Tvardi Therapeutics, Inc.
TVRD
$3.75
-$0.16-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 200.68% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 36.39% | -- | -- | -- | |
| Operating Income | -36.39% | -- | -- | -- | |
| Income Before Tax | -12.38% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -12.38% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -12.38% | -- | -- | -- | |
| EBIT | -36.39% | -- | -- | -- | |
| EBITDA | -36.55% | -- | -- | -- | |
| EPS Basic | 42.38% | -- | -- | -- | |
| Normalized Basic EPS | 42.38% | -- | -- | -- | |
| EPS Diluted | 18.00% | -- | -- | -- | |
| Normalized Diluted EPS | 42.18% | -- | -- | -- | |
| Average Basic Shares Outstanding | 69.76% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 70.92% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |